Bayer Still Confident Of Future Prospects Post-Xarelto

The German group has been talking up its pharmaceuticals division but analysts are not convinced it has addressed the elephant in the room that is the loss of patent protection for its blockbuster anticoagulant Xarelto in 2024.

Elephant
Difficult to ignore Xarelto patent expiries • Source: Shutterstock

More from Anticancer

More from Therapy Areas